Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Non-Current Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Non-Current Assets for 12 consecutive years, with $700000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 85.19% to $700000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $700000.0, a 85.19% increase, with the full-year FY2025 number at $700000.0, up 85.19% from a year prior.
  • Other Non-Current Assets was $700000.0 for Q4 2025 at ImmunityBio, up from $433000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $7.4 million in Q3 2021 to a low of $378000.0 in Q4 2024.
  • A 5-year average of $3.7 million and a median of $3.6 million in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: soared 160.78% in 2021, then tumbled 88.11% in 2025.
  • ImmunityBio's Other Non-Current Assets stood at $6.8 million in 2021, then decreased by 28.27% to $4.9 million in 2022, then crashed by 40.74% to $2.9 million in 2023, then crashed by 86.88% to $378000.0 in 2024, then soared by 85.19% to $700000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Other Non-Current Assets are $700000.0 (Q4 2025), $433000.0 (Q3 2025), and $3.6 million (Q2 2025).